PHOTOCURE ASA (PHO.OL) Stock Price, Forecast & Analysis
OSL:PHO • NO0010000045
PHO.OL Key Statistics, Chart & Performance
The current stock price of PHO.OL is 59.1 NOK. In the past month the price decreased by -14.22%. In the past year, price increased by 12.36%.
PHO.OL Technical Analysis
PHO.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PHO.OL. No worries on liquidiy or solvency for PHO.OL as it has an excellent financial health rating, but there are worries on the profitability.
PHO.OL Financial Highlights
Over the last trailing twelve months PHO.OL reported a non-GAAP Earnings per Share(EPS) of 0.03. The EPS decreased by -93.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.39% | ||
| ROA | 0.3% | ||
| ROE | 0.44% | ||
| Debt/Equity | 0 |
PHO.OL Forecast & Estimates
7 analysts have analysed PHO.OL and the average price target is 81.6 NOK. This implies a price increase of 38.07% is expected in the next year compared to the current price of 59.1.
For the next year, analysts expect an EPS growth of 916.42% and a revenue growth 12.05% for PHO.OL
PHO.OL Ownership
PHO.OL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.57 | 195.131B | ||
| SNW | SANOFI | 9.55 | 194.913B | ||
| 1SAN | SANOFI | 9.54 | 194.744B | ||
| 1MRK | MERCK KGAA | 14.92 | 55.76B | ||
| MRK | MERCK KGAA | 14.62 | 54.695B | ||
| UNC | UCB SA | 26.34 | 52.693B | ||
| UCB | UCB SA | 24.15 | 52.459B | ||
| 1BAYN | BAYER AG-REG | 8.75 | 41.984B | ||
| BAYN | BAYER AG-REG | 8.57 | 41.836B | ||
| IPN | IPSEN | 14.07 | 13.359B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Oslo Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About PHO.OL
Company Profile
Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. The company is headquartered in Oslo, Oslo and currently employs 101 full-time employees. The company went IPO on 2000-05-29. The firm is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Company Info
PHOTOCURE ASA
Hoffsveien 4
Oslo OSLO NO
Employees: 100
Phone: 4722062210
PHOTOCURE ASA / PHO.OL FAQ
What does PHO do?
Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. The company is headquartered in Oslo, Oslo and currently employs 101 full-time employees. The company went IPO on 2000-05-29. The firm is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
What is the stock price of PHOTOCURE ASA today?
The current stock price of PHO.OL is 59.1 NOK. The price decreased by -0.34% in the last trading session.
What is the dividend status of PHOTOCURE ASA?
PHO.OL does not pay a dividend.
What is the ChartMill technical and fundamental rating of PHO stock?
PHO.OL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of PHOTOCURE ASA (PHO.OL)?
The PE ratio for PHOTOCURE ASA (PHO.OL) is 1970. This is based on the reported non-GAAP earnings per share of 0.03 and the current share price of 59.1 NOK.
Would investing in PHOTOCURE ASA be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PHO.OL.
When does PHOTOCURE ASA (PHO.OL) report earnings?
PHOTOCURE ASA (PHO.OL) will report earnings on 2026-05-07.